Hospital-acquired pneumonia in the 21st century: A review of existing treatment options and their impact on patient care

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 12, 2006, Pages 1555-1569

  Koulenti, Despoina ^a   Rello, Jordi ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Hospital acquired pneumonia; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN; CLOXACILLIN; COLISTIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; EVERNINOMICIN; GENTAMICIN; ICLAPRIM; IMIPENEM; LINEZOLID; LIVE VACCINE; MEROPENEM; NETILMICIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; EMPIRICISM; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; LENGTH OF STAY; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; PATIENT CARE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; METHICILLIN RESISTANCE; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL; PRACTICE GUIDELINES; PSEUDOMONAS INFECTIONS; RESPIRATION, ARTIFICIAL; VANCOMYCIN;

EID: 33747038717     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.12.1555     Document Type: Review

References (130)

1. RICHARDS MJ, EDWARDS JR, CULVER DH, GAYNES RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Surveillance System. Crit. Care Med. (1999) 27(8):887-892.
2. VINCENT JL, BIHARI DJ, SUTER PM et al.: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of infection in Intensive Care (EPIC) Study. J. Am. Med. Assoc. (1995) 247:639-644.
3. KOLLEF MH: What is ventilator-associated pneumonia and why is it important? Resp Care (2005) 50(6):714-721.
4. RELLO J, AUSINA V, RICART M et al.: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest (1993) 104(4):1230-1235.
5. KOLLEF MH, SILVER P, MURPHY DM, TROVILLION E: The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest (1995) 108(6):1665-1662.
6. TORRES A, AZNAR R, GATELL JM et al.: Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Respir. Dis. (1990) 142(3):523-528.
7. CHASTRE J, FAGON JY: Ventilator-associated pneumonia. Am. J. Respir. Care. Med. (2002) 165:867-903.
8. FAGON JY, CHASTRE J, HANCE AJ et al.: Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. (1993) 94:281-288.
9. RELLO J, OLLENDORF DA, OSTER G et al.: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest (2002) 122:2115-2121.
10. AMERICAN THORACIC SOCIETY DOCUMENTS: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171: 388-416.
11. RELLO J, VALLES J: Mortality as an outcome in hospital-acquired pneumonia. Infect. Control Hosp. Epidemiol. (1998) 19(10):795-797.
12. RELLO J, RUE M, JUBERT P et al.: Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit. Care Med. (1997) 25(11):1862-1867.
13. HANES SD, DERMIKAN K, TOLLEY E et al.: Risk fectors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill patients. Clin. Infect. Dis. (2002) 35(3):228-235.
14. RELLO J, SOLE-VIOLAN J, SA-BORGES M et al.: Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med. (2005) 33(9):1983-1987.
15. RELLO J: Bench-to-bedside: therapeutic options and issues in the management of ventilator-associated pneumonia. Crit. Care (2005) 9:259-265.
16. RELLO J, TORRES A, RICART M et al.: Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin sensitive episodes. Am. J. Crit. Care Med. (1994) 150:1545-1549.
17. LUNA CM, VUJACICH P, NIEDERMAN MS et al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest (1997) 111:676-685.
18. MARKOWICZ P, WOLFF M, DJEDAINI K et al.: ARDS Study Group. Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome: incidence, prognosis and risk factors. Am. J. Respir. Crit. Care Med. (2000) 161:1942-1948.
19. MARIK PE, CAREAU P: The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest (1999) 115:178-183.
20. RELLO J, SA-BORGES M, CORREA H et al.: Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am. J. Respir. Crit. Care Med. (1999) 160(2):608-613.
21. BAUGHMAN RP: Microbiologic diagnosis of ventilator-associated pneumonia. Clin. Chest Med. (2005) 26(1):81-86.
22. NIEDERMAN MS: The clinical diagnosis of ventilator- associated pneumonia. Respir. Care (2005) 50(6):788-796.
23. CHASTRE J, COMBES A, LUYT CE: The invasive (quantitative) diagnosis of ventilator-associated pneumonia. Respir. Care (2005) 50(6):797-807.
24. MAYHALL CG: Ventilator-associated pneumonia or not? Contemporary diagnosis. Emerg. Infect. Dis. (2001) 7:200-204.
25. RELLO J, MARISCAL D, MARCH F et al.: Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am. J. Respir. Crit. Care Med. (1998) 157(3 Pt 1):912-916.
26. KOLLEF MH, WARD S: The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest (1998) 113(2):412-420.
27. CLEC'H C, TIMSIT JF, DE LASSENCE A et al.: Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med. (2004) 30(7):1327-1333.
28. IREGUI M, WARD S. SHERMAN G et al.: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest (2002) 122:262-268.
29. DUPONT H, MENTEC H, SOLLET JP, BLEICHNER C: Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. (2001) 27:355-362.
30. ALVAREZ-LERMA F: Modification of empiric antibiotic therapy in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. (1996) 22:387-394.
31. LUNA CM, ARUJ P, NIEDERMAN MS et al.: Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur. Respir. J. (2006) 27(1):158-164.
32. FOWLER RA, FLAVIN KE, BARR J et al.: Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest (2003) 123(3):835-844.
33. RELLO J, AUSINA V, RICART M et al.: Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med. (1994) 20(3):193-198.
34. NAMIAS N, SAMIIAN L, NINO D et al.: Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J. Trauma (2000) 49(4):638-45.
35. BABCOCK HM, ZACK JE, GARRISON T et al.: Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location. Infect. Control Hosp. Epidemiol (2003) 24:853-858.
36. SANDIUMENGE A, DIAZ E, BODI M, RELLO J: Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of 'The Tarragona Strategy'. Intensive Care Med. (2003) 29(6):876-883.
37. MERTENS AH, NAGLER JM, GALDERMANS et al.: Quality assessment of protected specimen brush samples by microscopic cell count. Am. J. Respir. Crit. Care Med. (1998) 157:1240-1243.
38. SALATA RA, LEDERMAN MM, SHLAES DM et al.: Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. Am. Rev. Respir. Dis (1987) 135(2):426-432.
39. MORRIS AJ, TANNER DC, RELLER LB: Rejection criteria for endotracheal aspirates from adults. J. Clin. Microbiol. (1993) 31(5):1027-9.
40. GALLEGO M, RELLO J: Diagnostic testing for ventilator-associated pneumonia. Clin. Chest Med. (1999) 20(3):671-679.
41. VALLES J, RELLO J, FERNANDEZ R et al.: Role of bronchoalveolar lavage in mechanically ventilated patients with suspected pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(7):549-558.
42. MARISCAL D, VALLES J, RELLO J: Value of direct examination of protected specimen brush (PSB) in intubated patients with suspected pneumonia (Abstract). Clin. Microbiol. Infect. (2001) 7(Suppl.):P1062.
43. GOLD H, MOELLERING R: Antimicrobial drug resistance. N. Engl. J. Med. (1996) 335:1445-1453.
44. GHEN DK, MC GEER A, DE AZAVEDO JC, LOE DE: Decreased susceptibility of Streptococcus pneumoniae in Canada. N. Engl. J. Med. (1999) 341:233-239.
45. TROUILLET JL, VUAGNAT A, COMBES A et al.: Pseudomonas aeruginosa ventilator-associated pneumonias: comparison of episodes due to piperacillin-resistant versus piperacillin-sensitive organisms. Clin. Infect. Dis. (2002) 34:1047-1054.
46. PATERSON DL: Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. (2004) 38(Suppl. 4):S341-S345.
47. NSEIR S. DIPOMPEO C, SOUBRIER S et al.: First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistance bacteria in the intensive care unit. Crit. Care Med. (2005) 33:283-289.
48. LIVERMORE DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. (2002) 34:634-640.
49. NIEDERMAN MS: Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit. Care Med. (2005) 33(2):443-444.
50. SANDIUMENGE A, DIAZ E, RODRIGUEZ A et al.: Impact of diversity of antibiotic use on the developement of antimicrobial resistance. J. Antimicrob. Chemother. (2006) 57:1197-1204.
51. RAYMOND DP, PELLETIER SJ, CRABREE TD et al.: Impact of rotating empiric antibiotic schedule on infectious mortality in the intensive care unit. Crit. Care Med. (2001) 29(6):1101-1108.
52. CRAIG WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. (1998) 26(1):1-10.
53. ZHANEL GG: Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr. Infect. Dis. Rep. (2001) 3(1):29-34.
54. PEA F, VIALE P, FURLANUT M: Antimicrobial therapy in critically ill patients. Clin. Pharmacokinet. (2005) 44:1009-1034.
55. PINDER M, BELLOMO R, LIPMAN J: Pharmacological principles of antibiiotic prescription in the critically ill. Anaesth. Intensive Care (2002) 30:134-144.
56. PARK D: Antimicrobial treatment of ventilator-associated pneumonia. Resp. Care (2005) 50(7):932-952.
57. HONEYBOURNE D: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr. Opin. Pulm. Med. (1997) 3(2):170-174.
58. KONIG C: Effect of pathological changes of pH, pO2 and pCO2 on the activity of antimicrobial agents in vitro. Eur. J. Clin. Microbiol. Infect. Dis. (1993) 12(7):519-526.
59. ADAIR CG, GORMAN SP, FERON BM et al.: Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med. (1999) 25(10):1072-1076.
60. MOSKOWITZ SM, FOSTER JM, EMERSON J, BURNS JL: Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. (2004) 42(5):1915-1922.
61. BERNABEU-WITTEL M, PICHARDO C, GARCIA-CURIEL A et al.: Pharmacokinetic/ pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. (2005) 11(4):319-325.
62. DAN M, TOROSSIAN K, WEISSBERG D, KITZES R: The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration. Eur. J. Clin. Pharmacol. (1993) 44(1):101-102.
63. COMETTA A, BAUMGARTNER JD, LEW D et al.: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. (1994) 38(6)1309-1313.
64. PAUL M, BENURI-SILBIGER I, SOARES-WEISER K, LEIBOVICI L: β-lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br. Med. J. (2004) 328(7441):668.
65. SAFDAR N, HANDELSMAN J, MAKI DG: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. (2004) 4:519-527.
66. MONTERO A, ARIZA J, CORBELLA X et al.: Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. (2004) 54(6):1085-1091.
67. KIRTLAND SH, CORLEY DE, WINTERBAUER RH et al.: The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest (1997) 112:445-457.
68. SOUWEINE B, VEBER B, BEDOS JP et al.: Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments. Crit. Care Med. (1998) 26:236-244.
69. VIDAUR L, GUALIS B, RODRIGUEZ A et al.: Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit. Care Med. (2005) 33(6):1248-1253.
70. RELLO J, VIDAUR L, SANDIUMENGE A et al.: De-escalation therapy in ventilator-associated pneumonia. Crit. Care Med. (2004) 32(11):2183-2190.
71. SINGH N, ROGERS P, ATWOOD CW et al.: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am. J. Respir. Crit. Care Med. (2000) 162(2 Pt 1):505-511.
72. CHASTRE J, WOLFF M, FAGON JY et al.: Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA (2003) 290:2588-2598.
73. IBRAHIM EH, WARD S, SHERMAN G, KOLLEF MH: A comparative analysis of patients with early-onset versus late-onset nosocomial pneumonia in the ICU setting. Chest (2000) 117(5):1434-1442.
74. MICEK ST, WARD S, FRASER VJ, KOLLEF MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest (2004) 125(5):1791-1799.
75. DENNESEN PJ, VAN DER VEN AJ, KESSELS AG et al.: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-pneumonia. Am. J. Respir. Crit. Care Med. (2001) 163(6):1371-1375.
76. RELLO J, DIAZ E, RODRIGUEZ A: Advances in the management of pneumonia in the intensive care unit: review of current thinking. Clin. Microbiol. Infect. (2005) 11 (Suppl. 5):30-38.
77. PACHON-IBANEZ ME, JIMENEZ-MEJIAS ME, PICHARDO C et al.: Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. (2004) 48:4479-4481.
78. RELLO J: Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J. Chemother. (2005) 17(Suppl. 1):12-22.
79. HOBAN DJ, BOUCHILLON SK, JOHNSON BM et al.: In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. (2005) 52:215-227.
80. FRITSCHE TR, STRABALA PA, SADER HS et al.: Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn. Microbiol. Infect. Dis. (2005) 52(3):209-213.
81. FRITSCHE TR, SADER HS, STILWELL MG et al.: Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. (2005) 52:187-193.
82. WOOTTON M, BOWKER KE, HOLT HA, MACCOWAN AP: BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J. Antimicrob. Chemother. (2002)49(3):535-539.
83. JONES RN, DESHPANDE LM, MUTNICK AH, BIEDENBACH DJ: In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resisrant staphylococci. J. Antimicrob. Chemother. (2002) 50:915-932.
84. SILVERMAN JA, MORTIN LI, VANPRAAGH AD et al.: Inhibition of daptomycin by pulmonary surfactant: in vitro modelling and clinical impact. J. Infect. Dis. (2005) 191:2149-2152.
85. TEDESCO KL, RYBAC MJ: Daptomycin. Pharmacotherapy (2004) 24:41-57.
86. ROUBY JJ, POETE P, MARTIN DE, LASSALE E et al.: Prevention of Gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. Intensive Care Med. (1994) 20(3):187-192.
87. WOOD GC, BOUCHER BA, CROCE MA et al.: Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy (2002) 22(8):972-982.
88. RELLO J, DIAZ E, RODRIGUEZ A: Etiology of ventilator-associated pneumonia. Clin. Chest Med. (2005) 26(1):87-95.
89. HAUSER AR, COBB E, BODI M et al.: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. (2002) 30(3):521-528.
90. SCHULERT GS, FELTMAN H, RABIN SD et al.: Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J. Infect. Dis. (2003) 188(11):1695-1706.
91. PIER G: Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev. Vaccines (2005) 4:645-656.
92. CUNHA BA: Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin. Microbiol. Infect. (2005) 11(Suppl. 4):33-42.
93. KOULENTI D, MYRIANTHEFS P, DIMOPOULOS G, BALTOPOULOS G: Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. Enferm. Infecc. Microbiol. Clin. (2005) 23(Suppl. 3):37-45.
94. WYSOCKI M, THOMAS F, WOLFF MA et al.: Comparison of continuous infusion with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J. Antimicrob. Chemother. (1995) 33:352-354.
95. JAMES JK, PALMER SM, LEVINE DP, RIBAK MJ: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob. Agents Chemother. (1996) 40:696-700.
96. CRAIG WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. (2003) 17(3):479-501.
97. MOISE-BRODER PA, FORREST A, BIRMINGHAM MC, SCHENTAG JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. (2004) 43(13):925-942.
98. GONZALEZ C, RUBIO M, ROMERO-VIVAS J: Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-sensitive organisms. Clin. Infect. Dis. (1999) 29:1171-1177.
99. PUJOL M, CORBELLA X, PEÑA C et al.: Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. (1998) 17:622-628.
100. WUNDERINK RG, RELLO J, CAMMARATA SK et al.: Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124:1789-1797.
101. RELLO J: Administración de antibióticos en las neumonías: visión desde el Mediterráneo. Enferm. Infecc. Microbiol. (2000) 18:59-61.
102. LAMER C, DE BECO V, SOLER P et al.: Analysis of vancomycin entry into the pulmonary epithelial lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. (1993) 37:2812-2886.
103. LUNDESTROM TS, SOBEL JD: Antibiotics for Gram-positive bacterial infections: vancomycin, teicoplanin, quinipristin/dalfopristin and linezolid. Infect. Dis. Clin. North Am. (2000) 14:463-474.
104. LAM AP, WUNDERINK RG: Methicillin-resistant S. aureus ventilator-associated pneumonia: strategies to prevent and treat. Semin. Respir. Crit. Care Med. (2006) 27:92-103.
105. HERNANDEZ G, RICO P, DIAZ E, RELLO J: Nosocomial lung infections in adult intensive care units. Microbes Infect. (2004) 6:1004-1014.
106. MOISE PA, FORREST A, BHAVNANI SM et al.: Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Health Syst. Pharm. (2000) 57:S4-S9.
107. NATHWANI D, TILLOTSON G: Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era? Int. J. Antimicrob. Agents (2003) 21:521-524.
108. PEA F, BROLLO L, VIALE P et al.: Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J. Antimicrob. Chemother. (2003) 51(4):971-975.
109. CONTE JE, GOLDEN JA, KIPPS J et al.: Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. (2002) 46:1475-1480.
110. TSIODRAS S, GOLD HS, SAKOULAS G et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358:207-208.
111. KOLLEF MH, RELLO J, GAMMARATA SK et al.: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intern. Care Med (2004) 30:388-394.
112. BERNARDO K, PAKULAT N, FLEER S et al.: Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob. Agents Chemother. (2004) 48:546-444.
113. FAGON J, PATRICK H, HAAS DW et al.: Treatment of Gram-positive nosocomial pneumonia: a prospective randomized comparison of quinapristin/dalfopristin versus vancomycin; Nosocomial Pneumonia Group. Am. J. Respir. Crit. Care Med. (2000) 161:753-762.
114. SILVER D, COHEN I, WEINBERG P: Recurrent Pseudomonas aeruginosa in an intensive care unit. Chest (1992) 101:194-198.
115. GARNACHO J, SOLE-VIOLAN J, SA-BORGES M et al.: Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit. Gare Med. (2003) 31:2478-2482.
116. RELLO J, DIAZ E: Acinetobacter baumannii: a threat for the ICU? Intensive Care Med (2003) 29(3):350-351.
117. GARNACHO-MONTERO J, ORTIZ-LEYBA C, FERNADEZ-HINOJOSA E et al.: Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. (2005) 31:649-655.
118. KOULENTI D, RELLO J: Gram-negative pneumonia. Aetiology and treatment. Curr. Opin. Pulm. Med. (2006) 12(3):198-204.
119. GARNACHO-MONTERO J, ORTIZ-LEYBA C, JIMENEZ-JIMENEZ FJ et al.: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. (2003) 31(10):1111-1118.
120. MASTERTON RG, TURNER PJ: Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). Int. J. Antimicrob. Agents (2006) 27:69-72.
121. JONES RN, MENDES C, TURNER PJ, MASTERTON R: An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn. Microbiol. Infect. Dis. (2005) 53:247-256.
122. PATERSON DL, KO WC, VON GOTTBERG A et al.: International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann. Intern. Med. (2004) 40:26-32.
123. PATERSON DL, KO WC, VON GOTTBERG A et al.: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis. (2004) 39:31-37.
124. SMITH MOLAND E, HANSON ND, HERRERA VL et al.: Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J. Antimicrob. Chemother. (2003) 51:711-714.
125. SHAH PM: The need for new therapeutic agents: what is the pipeline? Clin. Microbiol. Infect. (2005) 11(Suppl. 3):36-42.
126. APPELBAUM PC, JACOBS MR: Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. (2005) 8(5):510-517.
127. SELTZER E, DORR MB, GOLDSTEIN BP et al.: Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. (2003) 37:1298-1303.
128. JAUREGUI LE, BABAZADEH S, SELTZER E et al.: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2005) 41:1407-1415.
129. DESHPANDE L, RHOMBERG PR, FRITSCHE TR et al.: Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolate. Diagn. Microbiol. Infect. Dis. (2004) 50:73-75.
130. SCHNEIDER P, HAWSER S, ISLAM K: Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. (2003) 13:4217-4221.